Compare Altria Group Inc (MO) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs BIO-TECHNE Corp — how do they compare? Altria Group Inc trades at $73.23 (market cap $124.67B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Altria Group Inc is far larger — about 11.2× BIO-TECHNE Corp's market cap, and Altria Group Inc pays the higher dividend (5.68%). Which is the better fit depends on your goals.
| MO | TECH | |
|---|---|---|
Market Cap | $124.67B | $11.16B |
Sector | Consumer Staples | Health |
52-Week High | $74.66 | $72.12 |
52-Week Low | $54.72 | $43.31 |
Enterprise Value | $145.75B | $11.24B |
Dividend Yield | 5.68% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $72.99, down 1.64% on the day, with a P/E of 15.59 and strong net income margin of 39.52%. Recent earnings show mixed results, beating estimates in Q1 2026 but missing in Q4 2025. Technical indicators suggest a bullish trend with support at $73 and resistance at $75. The company maintains robust cash flow from operations at $9.29B and declared a $1.06 dividend payable in July 2026.
MO offers a high dividend yield and stable cash flows, appealing for income investors, but faces risks from declining smoking trends and regulatory pressures. Analyst consensus is bullish with a $71 price target, though revenue stagnation and debt levels warrant caution. The stock's defensive qualities provide stability amid market volatility.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
